Inhibikase Therapeutics Inc Stock Price, News & Analysis

Inhibikase Therapeutics (IKT) reported a net loss of $4.49 million, or $0.18 per share, for Q3 2022, compared to a loss of $4.47 million in Q3 2021. The company faces an FDA clinical hold on its IkT-148009 programs for Parkinson's and Multiple System Atrophy but reports no serious adverse events in its Phase 2a trial. R&D expenses decreased to $2.98 million from $3.15 million year-over-year. Inhibikase plans to initiate a bioequivalence study for IkT-001Pro in Q4 2022 and continues to present its findings at industry conferences.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced it will report its financial results for Q3 2022 after market close on November 14, 2022. A conference call will follow on November 15, 2022, at 8:00 a.m. ET, to discuss the results and provide corporate updates. The company focuses on developing therapeutics for Parkinson's disease and related disorders, with its lead program, IkT-148009, targeting neurodegeneration.

Inhibikase Therapeutics (Nasdaq: IKT) announced a clinical hold from the FDA on its IkT-148009 programs targeting Multiple Systems Atrophy (MSA) and Parkinson's disease (PD). The FDA's hold was communicated via email, with an official letter expected within 30 days. CEO Milton H. Werner stated there have been no serious adverse events in the ongoing trials and emphasized the company's commitment to addressing the FDA's concerns. Inhibikase focuses on developing treatments for neurodegenerative diseases, particularly those related to Parkinson's.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced CEO Milton Werner will present at the Inaugural Neurodegeneration Targets Conference on October 20, 2022, in Boston. The presentation titled ABL Kinase Inhibition as a Disease-Modifying Therapy for Parkinson's Disease will cover pre-clinical studies of IkT-148009, suggesting its potential for multi-organ repair with daily oral therapy. This aligns with the ongoing Phase 2a '201' clinical trial, focusing on Parkinson's disease and related disorders. Inhibikase specializes in therapeutics targeting neurodegeneration, including GI tract issues.

Inhibikase Therapeutics (Nasdaq: IKT) announced that Dr. Milton Werner, CEO, will present at the Grand Challenges in Parkinson's Disease Conference on September 28-29, 2022, in Grand Rapids, Michigan. The presentation focuses on IkT-148009, a potential disease-modifying therapy for Parkinson's disease, detailing outcomes from multiple pre-clinical studies. The session will occur at 3:00 PM EDT on September 28, highlighting the therapy's impact on multi-organ repair. Inhibikase is dedicated to developing treatments for neurodegenerative disorders related to Parkinson's disease.

Inhibikase Therapeutics reported positive results for its investigational drug IkT-148009, demonstrating high systemic exposure and good CNS penetration in older adults and Parkinson's patients, with no significant adverse events. The company is actively enrolling patients in the Phase 2a '201' clinical trial aimed at treating untreated Parkinson's disease. The data, presented at the International Congress of Parkinson's Disease and Movement Disorders, supports IkT-148009's safety profile and its potential to protect neurons and improve quality of life for patients.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced its participation at the International Congress of Parkinson's Disease and Movement Disorders in Madrid, Spain, from September 15-18, 2022. CEO Milton Werner, Ph.D., will present the abstract titled "IkT-148009 as a potential disease-modifying therapy in PD" during the GPT 6 session on September 16, 2022, from 1:00 – 3:00 p.m. CEST. Inhibikase focuses on developing therapies for Parkinson's disease and related disorders, with their lead program targeting the Abelson Tyrosine Kinase pathway to potentially modify the disease's course.

Inhibikase Therapeutics (IKT) announced the appointment of Gisele Dion to its Board of Directors, effective September 1, 2022, as she succeeds retiring member Elizabeth O'Farrell. Dion, who has extensive experience in public companies, will chair the Audit Committee and serve on the Compensation Committee. Milton H. Werner, CEO, expressed optimism about Dion's expertise in finance and mergers, which can enhance Inhibikase's efforts in developing therapeutics for Parkinson's and related diseases. Her previous roles include senior positions at Takeda Pharmaceuticals and Shire Pharmaceuticals.

Inhibikase Therapeutics (Nasdaq: IKT) announced the FDA's clearance of its Investigational New Drug application for IkT-001Pro, aimed at treating Chronic Myelogenous Leukemia (CML). The SMP letter allows the initiation of a bioequivalence study to assess safety compared to imatinib, with preclinical data suggesting IkT-001Pro may be 3.4 times safer than imatinib. This prodrug formulation aims to enhance patient adherence and quality of life by reducing gastrointestinal side effects. Inhibikase's pipeline also includes treatments for Parkinson's and related disorders.